Evidence map›Paper›PMID 38720139›Full record

ArticleJournal of neurology2024

The chronic use of serotonin norepinephrine reuptake inhibitors facilitates dyskinesia priming in early Parkinson's disease.

Massimo Marano, Andrea Pilotto, Alessandro Padovani, Deepak Gupta, Giorgio Vivacqua, Alessandro Magliozzi, Vincenzo Di Lazzaro, Manolo Carta, Mario Meloni

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Body image appearance in Parkinson's disease patients on device aided therapies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Massimo MaranoNeurology, Neurophysiology, Neurobiology and Psychiatry Unit, Department of Medicine, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, 00128, Rome, Italy. m.marano@policlinicocampus.it.ORCID http://orcid.org/0000-0001-9885-3666
Andrea PilottoNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Alessandro PadovaniNeurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Deepak GuptaDepartment of Neurological Sciences, Larner College of Medicine, University of Vermont, Burlington, VT, USA.
Giorgio VivacquaLaboratory of Microscopic and Ultrastructural Anatomy, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 21, 00128, Roma, Italy.
Alessandro MagliozziNeurology, Neurophysiology, Neurobiology and Psychiatry Unit, Department of Medicine, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, 00128, Rome, Italy.
Vincenzo Di LazzaroNeurology, Neurophysiology, Neurobiology and Psychiatry Unit, Department of Medicine, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo 200, 00128, Rome, Italy.
Manolo CartaDepartment of Biomedical Sciences, University of Cagliari, Cagliari, CA, Italy.
Mario MeloniNeurology Unit, Azienda Ospedaliera Universitaria di Cagliari, Cagliari, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundParkinson's disease (PD) patients are frequently exposed to antidepressant medications (ADMs). Norepinephrine (NE) and serotonin (5HT) systems have a role in levodopa-induced dyskinesias (LID) pathophysiology.

methodsWe performed a longitudinal analysis on the PPMI cohort including drug-naïve PD patients, who are progressively exposed to dopamine replacement therapies (DRTs) to test the effect of ADM exposure on LID development by the 4th year of follow-up.

resultsLID prevalence (according to MDS UPDRS score 4.1 ≥ 1) was 16% (42/251); these patients were more likely women (p = 0.01), had higher motor (p < 0.001) and depression scores (p = 0.01) and lower putaminal DAT binding ratio (p = 0.01). LID were associated with the exposure time to L-DOPA (2.2 ± 1.07 vs 2.6 ± 0.9, p = 0.02) and to the exposure to ADMs, in particular to SNRI (4.8% vs 21.4%, p < 0.001). The latter persisted after correcting for significant covariates (e.g., disease duration, cognitive status, motor impairment, depression, dopaminergic denervation). A similar difference in LID prevalence in PD patients exposed vs non-exposed to SNRI was observed on matched data by the real-world TriNetX repository (22% vs 13%, p < 0.001). DISCUSSION: This study supports the presence of an effect of SNRI on LID priming in patients with early PD. Independent prospective cohort studies are warranted to further verify such association.

Indexed as

Antiparkinson AgentsDyskinesia, Drug-InducedLevodopaParkinson DiseaseAgedFemaleHumansLongitudinal StudiesMaleMiddle AgedSerotonin and Noradrenaline Reuptake InhibitorsAntiparkinson AgentsLevodopaSerotonin and Noradrenaline Reuptake InhibitorsDepressionLevodopa-induced dyskinesiasLocus coeruleusMotor fluctuationsNoradrenalineSerotonin

Identifiers

PMID38720139

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.